Company profile: Hansa Biopharma
1.1 - Company Overview
Company description
- Provider of immunomodulatory treatments for rare immunological diseases, including Imlifidase, a first-generation IgG-cleaving enzyme for rapid inactivation of IgG antibodies via single intravenous treatment. Offers a proprietary enzyme technology platform targeting pathogenic antibodies across transplantation, autoimmunity, gene therapy and oncology, supported by strategic partnerships and sustainability initiatives.
Products and services
- Enzyme Technology Platform: Proprietary platform architects antibody-targeting products to target pathogenic antibodies in rare immunologic conditions across transplantation, autoimmunity, gene therapy, and oncology
- Imlifidase: First-generation IgG-cleaving enzyme engineered for rapid inactivation of IgG antibodies in plasma and tissue via a single intravenous treatment
- Therapeutic Areas: Rare-immunologic focus encompasses transplant rejection, genetic diseases, autoimmune conditions, and cancer, guiding applications of antibody-targeting technologies to critical unmet medical needs
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Hansa Biopharma
Santa Ana Bio
HQ: United States
Website
- Description: Provider of precision immunology drug development for autoimmune and inflammatory diseases, using single-cell genomics and advanced analytics to develop drugs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Santa Ana Bio company profile →
Avalo Therapeutics
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical therapies developing monoclonal antibodies and a fusion protein for inflammatory diseases, including AVTX-009 (anti-IL-1β), quisovalimab (anti-LIGHT), AVTX-008 (BTLA agonist fusion protein), and AVTX-002 (fully human anti-LIGHT, in Phase 2 for non-eosinophilic asthma, inflammatory bowel diseases, and COVID-19 acute respiratory distress syndrome).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Avalo Therapeutics company profile →
CytoDyn
HQ: United States
Website
- Description: Provider of biotechnology therapies developing Leronlimab, a CCR5-targeting humanized monoclonal antibody for HIV to prevent viral entry into T-cells; exploring uses in NASH to address liver health, fibrosis and cirrhosis; oncology to inhibit tumor growth and metastasis; COVID-19 to modulate immune response and potentially reduce inflammation; and pre-clinical glioblastoma studies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CytoDyn company profile →
180 Life Sciences
HQ: United States
Website
- Description: Provider of novel drug development focused on treating distinct inflammatory diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full 180 Life Sciences company profile →
Medsenic
HQ: France
Website
- Description: Provider of drug development and manufacturing focused on drugs for the treatment of autoimmune diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medsenic company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Hansa Biopharma
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Hansa Biopharma
2.2 - Growth funds investing in similar companies to Hansa Biopharma
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Hansa Biopharma
4.2 - Public trading comparable groups for Hansa Biopharma
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →